Latvija - latviešu - Zāļu valsts aģentūra

novartis hrvatska d.o.o, croatia - tobramicīns - acu ziede - 3 mg/g

Latvija - latviešu - Zāļu valsts aģentūra

novartis s.r.o., czech republic - tobramicīns - acu ziede - 3 mg/g

Latvija - latviešu - Zāļu valsts aģentūra

novartis (hellas) a.e.b.e., greece - tobramicīns - acu pilieni, šķīdums - 3 mg/ml

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doksorubicīns - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

Latvija - latviešu - Zāļu valsts aģentūra

medac gesellschaft für klinische spezialpräparate mbh, germany - mitomicīns - pulveris injekciju/infūziju šķīduma pagatavošanai vai intravezikāli lietojama šķīduma pagatavošanai - 1 mg/ml

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

merial s.a.s., francija - spiramicīns - šķīdums injekcijām - 600000 iu/ml - liellopi

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

ceva sante animale., francija - spiramicīns - šķīdums injekcijām - 600000 iu/ml - cūkas; liellopi

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - doksorubicīna hidrohlorīds - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastiski līdzekļi - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

tlc biopharmaceuticals b.v. - doksorubicīna hidrohlorīds - breast neoplasms; ovarian neoplasms - antineoplastiski līdzekļi - Ārstēšanai krūts un olnīcu vēzis.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

gilead sciences ireland uc - aztreonam lizīns - cystic fibrosis; respiratory tract infections - antibakteriālas līdzekļi sistēmiskai lietošanai, - cayston ir indicēts pseudomonas aeruginosa izraisītu hronisku plaušu infekciju nomācošai terapijai pacientiem ar cistisko fibrozi (cf) vecumā no 6 gadiem. jāņem vērā oficiālās vadlīnijas par piemērotu izmantot antibakteriālas vielas.